

Pralsetinib ARROW

**PRELIMINARY SCORE**

**CURATIVE**



**NON-CURATIVE**



**ADJUSTMENTS**

**Quality of life**



Not qualified for an ESMO-MCBS credit



**Serious and disabling adverse effects**



**Other adjustments**



Pralsetinib ARROW

**SCORE**

**CURATIVE**



Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Thoracic Malignancies  
 Therapeutic Indication: Treatment for adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA-approved test  
 Experimental Arm: Pralsetinib  
 Control Arm: Single arm



